Women Live Longer After TAVR than Men

Why It Matters

Understanding the gender gap in TAVR outcomes can refine patient selection, lower mortality, and optimize resource use in an increasingly costly procedure.

Key Takeaways

• 600‑patient Norwegian TAVR study: women outlived men after three years
• Women had more concentric LV hypertrophy and preserved ejection fraction pre‑procedure
• Baseline abnormal ECG and atrial fibrillation strongly predicted mortality, especially in men
• Lower periostin levels in women indicate reduced cardiac fibrosis after TAVR
• Results suggest sex‑specific risk models could improve TAVR patient selection

Pulse Analysis

Transcatheter aortic valve replacement has reshaped the treatment landscape for severe aortic stenosis, offering a less invasive alternative to open‑heart surgery. Since its guideline endorsement for patients over 75 and high‑risk younger cohorts, TAVR volumes have surged worldwide, driving up procedural expenditures that often exceed surgical costs. Clinicians therefore face pressure to identify patients who will derive the greatest long‑term benefit, balancing clinical outcomes against financial sustainability.

The Norwegian TAVI‑NOR study examined 600 consecutive TAVR recipients, revealing a striking sex disparity. While early mortality was comparable, women demonstrated a statistically significant survival advantage after the three‑year mark, translating into fewer deaths over a five‑year horizon. The authors attribute this to several physiological factors: women more frequently exhibited concentric left‑ventricular hypertrophy and preserved ejection fraction, both of which tolerate the hemodynamic shift post‑valve implantation better than the eccentric remodeling common in men. Additionally, men presented higher rates of baseline atrial fibrillation and abnormal ECGs, both strong predictors of adverse outcomes, and women showed lower periostin levels, suggesting reduced cardiac fibrosis.

These insights compel a reevaluation of current TAVR risk models, which largely overlook sex‑specific cardiac biology. Incorporating variables such as left‑ventricular geometry, periostin biomarkers, and arrhythmia burden could sharpen patient stratification, ensuring that the procedure’s high upfront cost is allocated to those most likely to achieve durable survival. As the device market expands and reimbursement scrutiny intensifies, manufacturers and providers alike will benefit from data‑driven, gender‑aware selection protocols that improve outcomes and contain costs.